Episode

Episode 502: AUA 2026 and FDA bladder cancer meeting

Podcast: The Uromigos
Published: May 20, 2026
Duration seconds: 2116
Processing state: not_requested
Canonical source: https://podcasters.spotify.com/pod/show/the-uromigos/episodes/Episode-502-AUA-2026-and-FDA-bladder-cancer-meeting-e3jlaf2
Audio: https://anchor.fm/s/13347ea8/podcast/play/120285090/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-20%2F424548128-44100-2-4ce93ed7c5d5a.m4a
JSON: /v1/public/podcasts/the-uromigos-1214845/episodes/episode-502-aua-2026-and-fda-bladder-cancer-meeting
Markdown: /podcast/the-uromigos-1214845/episode-502-aua-2026-and-fda-bladder-cancer-meeting.md

Actions

POST https://stenobird.com/v1/public/podcasts/the-uromigos-1214845/episodes/episode-502-aua-2026-and-fda-bladder-cancer-meeting/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/the-uromigos-1214845/episode-502-aua-2026-and-fda-bladder-cancer-meeting.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

In this episode, Brian and Tom engage with Ashish Kamat to discuss the recent FDA meeting focused on bladder cancer treatments, particularly the nuances between CIS and papillary disease. They explore the challenges of drug approvals, the importance of randomized trials, and the emerging data on Deltalimagene, a non-viral gene therapy. The conversation highlights the complexities of treatment options, the need for robust clinical trials, and the future landscape of bladder cancer therapies